279 related articles for article (PubMed ID: 32093530)
21. Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis.
Failing CJ; Boehnke KF; Riebschleger M
Pediatr Rheumatol Online J; 2021 Dec; 19(1):171. PubMed ID: 34903213
[TBL] [Abstract][Full Text] [Related]
22. The impacts of potency, warning messages, and price on preferences for Cannabis flower products.
Shi Y; Cao Y; Shang C; Pacula RL
Int J Drug Policy; 2019 Dec; 74():1-10. PubMed ID: 31382201
[TBL] [Abstract][Full Text] [Related]
23. Infodemiological Examination of Personal and Commercial Tweets About Cannabidiol: Term and Sentiment Analysis.
Turner J; Kantardzic M; Vickers-Smith R
J Med Internet Res; 2021 Dec; 23(12):e27307. PubMed ID: 34932014
[TBL] [Abstract][Full Text] [Related]
24. Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science.
Marinotti O; Sarill M
J Diet Suppl; 2020; 17(5):517-526. PubMed ID: 32543253
[TBL] [Abstract][Full Text] [Related]
25. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.
Gurley BJ; Murphy TP; Gul W; Walker LA; ElSohly M
J Diet Suppl; 2020; 17(5):599-607. PubMed ID: 32431186
[TBL] [Abstract][Full Text] [Related]
26. Expectations and knowledge of cannabidiol therapy for childhood epilepsy - A German caregiver survey.
Klotz KA; Schönberger J; Nakamura L; San Antonio-Arce V; Bast T; Wiemer-Kruel A; Schubert-Bast S; Borggraefe I; Syrbe S; Jacobs J
Epilepsy Behav; 2020 Oct; 111():107268. PubMed ID: 32645621
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Users' Attitudes Toward Cannabidiol on Social Media Platforms: Topic Modeling Study.
Li Y; Yan X; Wang Z; Ma M; Zhang B; Jia Z
JMIR Public Health Surveill; 2023 Jan; 9():e34132. PubMed ID: 36630175
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study.
Binkowska AA; Jakubowska N; Redeł A; Laskowska S; Szlufik S; Brzezicka A
Front Psychiatry; 2024; 15():1356009. PubMed ID: 38487574
[TBL] [Abstract][Full Text] [Related]
29. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
30. Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter.
Soleymanpour M; Saderholm S; Kavuluru R
Proceedings (IEEE Int Conf Bioinformatics Biomed); 2021 Dec; 2021():3083-3088. PubMed ID: 35096472
[TBL] [Abstract][Full Text] [Related]
31. Community pharmacists' lack of knowledge and confidence in non-prescription cannabidiol products.
Patel S; Doroudgar S; Ip EJ
Res Social Adm Pharm; 2021 Jul; 17(7):1356-1360. PubMed ID: 33041209
[TBL] [Abstract][Full Text] [Related]
32. The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products.
Li J; Carvajal R; Bruner L; Kaminski NE
Food Chem Toxicol; 2021 Nov; 157():112600. PubMed ID: 34626752
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway.
Koturbash I; MacKay D
J Diet Suppl; 2020; 17(5):487-492. PubMed ID: 32715797
[TBL] [Abstract][Full Text] [Related]
34. Assessment of hemp oil-based cannabidiol use in a community-based pharmacy setting.
Gicewicz E; Gatewood SS; Kaefer TN; Nadpara P; Goode JR
J Am Pharm Assoc (2003); 2021; 61(4S):S49-S56. PubMed ID: 33745856
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol use in France in 2022: Results from a nationwide representative sample of adults.
Barré T; Lahaie E; Di Beo V; Carrieri P; Andler R; Nguyen-Thanh V; Beck F
Drug Alcohol Rev; 2024 Jul; 43(5):1294-1304. PubMed ID: 38561958
[TBL] [Abstract][Full Text] [Related]
36. Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis.
Mathur K; Vuppalanchi V; Gelow K; Vuppalanchi R; Lammert C
Dig Dis Sci; 2020 Jan; 65(1):322-328. PubMed ID: 31363952
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.
Elms L; Shannon S; Hughes S; Lewis N
J Altern Complement Med; 2019 Apr; 25(4):392-397. PubMed ID: 30543451
[TBL] [Abstract][Full Text] [Related]
38. Access to cannabidiol without a prescription: A cross-country comparison and analysis.
McGregor IS; Cairns EA; Abelev S; Cohen R; Henderson M; Couch D; Arnold JC; Gauld N
Int J Drug Policy; 2020 Nov; 85():102935. PubMed ID: 32919298
[TBL] [Abstract][Full Text] [Related]
39. High Prevalence of Cannabidiol Use Within Male Professional Rugby Union and League Players: A Quest for Pain Relief and Enhanced Recovery.
Kasper AM; Sparks SA; Hooks M; Skeer M; Webb B; Nia H; Morton JP; Close GL
Int J Sport Nutr Exerc Metab; 2020 Sep; 30(5):315-322. PubMed ID: 32732454
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study.
Capano A; Weaver R; Burkman E
Postgrad Med; 2020 Jan; 132(1):56-61. PubMed ID: 31711352
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
